GCC gMG prevalence is estimated at 6,000-10,000 patients, and within that base, fewer than 50 are currently on biologic therapy, the tightest funnel narrowing of any market in this set.
GCC gMG prevalence is estimated at 6,000-10,000 patients (14-20 per 100,000), the figure this model uses as total prevalence because it is the region's primary epidemiology estimate. A separate research angle, built for launch-readiness planning, cites 800-1,200 patients as a population base; that figure describes a narrower, specialist-referral-confirmed segment engaged with tertiary neurology, not a competing total prevalence estimate, and this model does not treat it as one. Diagnosis itself is the first bottleneck: an estimated 30-40% of GCC MG patients are initially misdiagnosed as thyroid myopathy given the region's high background thyroid disease prevalence, and AChR-antibody testing is concentrated at roughly 20 centres region-wide.
Within the 6,000-10,000 total, 200-300 patients are refractory, immunosuppressant-inadequate candidates for a novel agent, managed almost entirely by 8-10 tertiary-centre neurologists across KSA, UAE, and Qatar. Fewer than 50 GCC patients are currently on biologic therapy (efgartigimod or, rarely, eculizumab), reflecting how early the region is in novel-agent uptake rather than a shortage of eligible patients. NPHC has no formal refractory-gMG novel-agent programme today, so this narrow on-therapy count is a function of the payer and referral pathway, not the underlying disease burden.
GCC gMG funnel - from total prevalence to the on-biologic-therapy cohort
| Funnel Stage | Population | Source |
|---|---|---|
| Estimated total GCC gMG prevalence | 6,000-10,000 | GCC neurology network data / Al-Shubaili AF, Eur Neurol 2012 |
| Specialist-referral-confirmed segment (narrower base) | 800-1,200 | AXLRx Launch Readiness research base |
| Refractory, immunosuppressant-inadequate candidates | 200-300 | AXLRx Launch Readiness research base |
| Currently on biologic therapy | Fewer than 50 | AXLRx Launch Readiness research base |
Sources: Al-Shubaili AF, Eur Neurol 2012; GCC neurology network data; AXLRx Myasthenia Gravis GCC Launch Readiness research base (GCC neurology society gMG working group, KFSH&RC neuromuscular case series).
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Why 6,000-10,000 is used as total prevalence
- how the narrower 800-1,200 figure describes a specialist-referral-confirmed segment rather than a competing total
- the reconciliation logic applied throughout the model
Delivers
- Refractory population sizing (200-300)
- current biologic-therapy count (fewer than 50)
- the 8-10 tertiary-centre neurologist concentration managing this population
Delivers
- 30-40% thyroid-myopathy misdiagnosis rate
- the ~20-centre AChR-antibody testing network
- the diagnostic-delay-corrected population estimate
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Reconciling the 6,000-10,000 epidemiology estimate against the narrower 800-1,200 specialist-referral figure
- Pressure-tested before the rest of the model is built out
- 6,000-10,000 estimated total GCC prevalence
- The thyroid-myopathy diagnostic confounder
- ~20 centres with AChR-antibody testing capability
- The 8-10 tertiary neurologists managing confirmed gMG
- 200-300 refractory, immunosuppressant-inadequate patients
- The narrower 800-1,200 specialist-referral-confirmed segment
- Fewer than 50 patients currently on biologic therapy
- NPHC's absence of a formal refractory-gMG programme
- Which diagnostic-delay assumption moves the addressable pool most
- Scenario ranges across the epidemiology and referral-confirmed bases
- Patient volume by horizon under conservative, base, and aggressive scenarios
- Revenue translation inputs
- The open questions your forecasting team must close before the model is finalised
- Structured for an internal forecast-review session
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx patient flow model is built on a five-layer funnel: population, disease burden (E1), diagnosis and specialist capture (E2), treatment and biomarker eligibility (E3), market access (E4), then Year 1-3-5 projections across three scenarios. Where a narrower research figure describes a different denominator than the total-prevalence estimate, this model states that difference explicitly rather than treating the two as competing totals.
GCC gMG sources: Al-Shubaili AF's GCC case series in the European Neurology journal, the GCC neurology network database, and the population and access research built for the AXLRx GCC Launch Readiness assessment, which draws on the GCC neurology society gMG working group and KFSH&RC neuromuscular case series.
- Total GCC prevalence (6,000-10,000) verified against Al-Shubaili AF, Eur Neurol 2012 and GCC neurology network data
- Specialist-referral-confirmed segment (800-1,200) and refractory sizing (200-300) verified against the AXLRx Launch Readiness research base
- Current on-biologic-therapy count (fewer than 50) verified against the AXLRx Launch Readiness research base and GCC neurology society gMG working group
Frequently asked questions
Commission this model
AXLRx delivers rare-disease patient flow models built for forecasting and launch teams sizing the GCC gMG opportunity. Custom model in 72 hours.
Specify your indication, market, and cohort definition.
AXLRx analyst confirms funnel scope and comparator set before building.
Research-verified patient flow model in 72 hours with optional analyst readout.